Nordic Nanovector ASA
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nordic Nanovector ASA
The company has sought to develop antibodies purpose-built for delivering radiotherapy rather than repurposing existing antibodies for that purpose, as some other players have done.
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Nordic Nanovector GmbH
- Nordic Nanovector Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.